Surat : The diamond city of Surat witnessed a confluence of renowned Indian and international doctors, all united by a common mission: to raise awareness about a revolutionary new treatment for peripheral vascular disease (PVD). The spotlight shone brightly on Concept Medical’s MagicTouch, the world’s first Sirolimus-coated balloon, offering a ray of hope for millions suffering from this debilitating condition.
Dr. Sahil Parikh (New York), Dr. Eric Secemsky (Boston), Dr. Edward Choke (Singapore), and Indian stalwarts like Dr. Sameer Dani and Dr. Girish Reddy, came together to discuss cutting-edge advancements in vascular medicine, strategies for halting PVD progression, and effective patient relief measures.
At the heart of the discussion stood MagicTouch, a testament to Indian innovation. This USFDA-approved, CE-marked marvel has already garnered widespread acclaim in Europe, and is rapidly gaining traction in India. Its popularity stems from its remarkable efficacy in treating PVD, a disease that often goes unnoticed until it’s too late.
“Patients often mistake the pain in their arms or legs for simple discomfort, resorting to ointments or painkillers,” lamented Dr. Sahil Parikh, highlighting the critical need for awareness. “But when the disease progresses, it can lead to complete blood circulation stoppage, potentially culminating in gangrene and even amputation, especially for diabetic patients.”
Traditional treatments like stents and Percutaneous Old Balloon Angioplasty (POBA) were acknowledged, but their limitations were also addressed. Dr. Parikh emphasized the potential dangers of Paclitaxel-coated balloons, deeming them unsuitable for long-term human use. He further pointed out the impermanence of POBA, often necessitating repeated interventions.
This is where MagicTouch shines. Its innovative Sirolimus coating prevents cell proliferation within the treated artery, effectively minimizing the need for repeat procedures. This is particularly beneficial for patients with blockages below the knee, where stenting is often impractical.
“MagicTouch PTA is a game-changer,” declared Dr. Parikh, his voice filled with conviction. “It’s a safe, effective, and permanent solution for many PVD patients.”
“MagicTouch is a testament to our dedication to patient well-being,” expressed Dr. Manish Doshi, Managing Director of Concept Medical. “We’re proud to be the first Indian company to receive two USFDA IDE approvals in the peripheral treatment space, and we remain dedicated to pushing the boundaries of vascular disease treatment.”
